Trial ID or NCT#

NCT02341560

Status

not recruiting iconNOT RECRUITING

Purpose

This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.

Official Title

A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Eligibility Criteria

Ages Eligible for Study: 50 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Y. Joyce Liao, MD, PhD
Y. Joyce Liao, MD, PhD
Professor of Ophthalmology and of Neurology
Shannon Beres, MD
Shannon Beres, MD
Neuro-ophthalmology specialist, General neurologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Ophthalmology
Heather E. Moss, MD, PhD
Heather E. Moss, MD, PhD
Neuro-ophthalmology specialist
Associate Professor of Ophthalmology and of Neurology
Theodore Leng, MD, FACS
Theodore Leng, MD, FACS
Ophthalmologist
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
Steven Sanislo, MD
Steven Sanislo, MD
Ophthalmologist
Clinical Professor, Ophthalmology

Contact us to find out if this trial is right for you.

CONTACT

Mariana Nunez
(650) 497-7846